Coldplasmatech

Coldplasmatech GmbH, a medical technology company, was established in June 2015 as a spin-off from the Leibniz Institute for Plasma Science and Technology in Greifswald, Germany. The company was co-founded by CEO Dr. Carsten Mahrenholz and COO Tobias Güra. Dr. Mahrenholz holds a PhD in chemistry and an MBA, with a background as a consultant and CEO of a high-tech transfer company before pioneering this venture in plasma medicine. His co-founder, Tobias Güra, is an expert in health economics and reimbursement, overseeing the company's operational processes.

The company is addressing critical challenges in modern medicine, specifically chronic wounds and the rise of multi-resistant bacteria. The market for chronic and acute wounds represents a significant healthcare cost, estimated at $50 billion annually in the United States alone. Coldplasmatech's business is centered on developing and marketing a novel treatment that shifts the focus from ongoing wound care to active wound healing. Their primary clients are medical institutions, such as hospitals and wound care centers, with their technology already in use at prominent facilities like Hannover Medical School and the University Heart Center Hamburg. The company generates revenue through the sale of its medical devices and consumables. To expand its international presence, Coldplasmatech entered a strategic partnership with Royal Biologics, a US-based leader in orthobiologic and advanced wound care solutions.

Coldplasmatech has developed a proprietary Cold Atmospheric Plasma (CAP) technology, which consists of the CPT®cube, a fully automated control device, and the CPT®patch, a specialized single-use wound dressing. This system, registered in the EU as a Class IIb medical device, creates cold plasma directly on the wound. The process is designed to be painless and takes only two minutes to complete. The plasma's bioactive properties work to reduce bacterial load, including antibiotic-resistant pathogens, while stimulating cellular regeneration, improving blood circulation, and promoting the formation of new blood vessels. The technology is unique in its ability to treat large and deep wound areas effectively. The efficacy of this treatment is being evaluated in the POWER study, the world's largest randomized controlled trial for chronic lower leg wounds, which has shown a significant acceleration in wound closure.

Keywords: plasma medicine, chronic wound care, antimicrobial resistance, medical devices, wound healing, medtech, advanced wound care, cold plasma, bacterial inactivation, tissue regeneration